Arvinas, Inc.

34.08 USD
-0.08 (-0.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arvinas, Inc. stock is up 127.35% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 5 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 CALL. 67% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
19 Oct 13:37 19 Apr, 2024 17.50 CALL 90 0

About Arvinas, Inc.

Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)

  • Jefferies
    Wed Dec 6, 11:07
  • Guggenheim
    Mon Nov 20, 06:48
  • Morgan Stanley
    Mon Nov 13, 09:14